Lumos Pharma Inc logo

LUMO - Lumos Pharma Inc Share Price

$13.6 -0.8  -5.2%

Last Trade - 26/02/21

Sector
Healthcare
Size
Small Cap
Market Cap £81.0m
Enterprise Value £5.21m
Revenue £403k
Position in Universe 4919th / 6715
Bullish
Bearish
Unlock LUMO Revenue
Momentum
Relative Strength (%)
1m -25.3%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -63.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
172.6 68.5 35.8 28.7 12.5 0.94 0.14 -64.8%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, LumosPharma Inc revenues increased from $0K to $128K. Net lossapplicable to common stockholders decreased 59% to $3.9M.Revenues reflect an increase in demand for the Company'sproducts and services due to favorable market conditions.Lower net loss reflects Other income (expense), netincrease from $0K to $6.3M (income), Interest Incomeincrease from $56K to $246K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

LUMO Revenue Unlock LUMO Revenue

Net Income

LUMO Net Income Unlock LUMO Revenue

Normalised EPS

LUMO Normalised EPS Unlock LUMO Revenue

PE Ratio Range

LUMO PE Ratio Range Unlock LUMO Revenue

Dividend Yield Range

LUMO Dividend Yield Range Unlock LUMO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
LUMO EPS Forecasts Unlock LUMO Revenue
Profile Summary

Lumos Pharma, Inc., formerly NewLink Genetics Corporation, is a clinical stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for rare diseases. Its lead product candidate is LUM-201, an oral growth hormone stimulating therapeutic, is in late stage clinical development for the treatment of Pediatric Growth Hormone Deficiency (PGHD). LUM-201 is an orally administered small molecule that promotes the secretion (secretagogue) of Growth Hormone (GH) from the pituitary gland. LUM-201 acts as an agonist of the GH Secretagogue Receptor to stimulate GH release. The Company’s pipeline features development programs in rare diseases associated with growth hormone deficiencies.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated June 4, 1999
Public Since November 11, 2011
No. of Shareholders: 79
No. of Employees: 28
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 8,297,058
Free Float (0.0%)
Eligible for
ISAs
SIPPs
LUMO Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for LUMO
Upcoming Events for LUMO
Frequently Asked Questions for Lumos Pharma Inc
What is the Lumos Pharma Inc share price?

As of 26/02/21, shares in Lumos Pharma Inc are trading at $13.6, giving the company a market capitalisation of £81.0m. This share price information is delayed by 15 minutes.

How has the Lumos Pharma Inc share price performed this year?

Shares in Lumos Pharma Inc are currently trading at $13.6 and the price has moved by 2.8% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Lumos Pharma Inc price has moved by -20.7% over the past year.

What are the analyst and broker recommendations for Lumos Pharma Inc?

Of the analysts with advisory recommendations for Lumos Pharma Inc, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Lumos Pharma Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Lumos Pharma Inc next release its financial results?

Lumos Pharma Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Lumos Pharma Inc dividend yield?

Lumos Pharma Inc does not currently pay a dividend.

Does Lumos Pharma Inc pay a dividend?

Lumos Pharma Inc does not currently pay a dividend.

When does Lumos Pharma Inc next pay dividends?

Lumos Pharma Inc does not currently pay a dividend.

How do I buy Lumos Pharma Inc shares?

To buy shares in Lumos Pharma Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Lumos Pharma Inc?

Shares in Lumos Pharma Inc are currently trading at $13.6, giving the company a market capitalisation of £81.0m.

Where are Lumos Pharma Inc shares listed? Where are Lumos Pharma Inc shares listed?

Here are the trading details for Lumos Pharma Inc:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: LUMO
What kind of share is Lumos Pharma Inc?

Based on an overall assessment of its quality, value and momentum, Lumos Pharma Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Lumos Pharma Inc share price forecast 2021?

Shares in Lumos Pharma Inc are currently priced at $13.6. At that level they are trading at 0.143% discount to the analyst consensus target price of 0.00.

Analysts covering Lumos Pharma Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.498 for the next financial year.

How can I tell whether the Lumos Pharma Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lumos Pharma Inc. Over the past six months, the relative strength of its shares against the market has been -18.21%. At the current price of $13.6, shares in Lumos Pharma Inc are trading at -16.89% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Lumos Pharma Inc PE Ratio?

We were not able to find PE ratio data for Lumos Pharma Inc.

Who are the key directors of Lumos Pharma Inc?

Lumos Pharma Inc's management team is headed by:

Nicholas Vahanian - DRC
Thomas Raffin - LED
Carl Langren - CFO
Eugene Kennedy - OTH
Chad Johnson - IND
Lori Lawley - SVF
Bradley Powers - GCN
Richard Hawkins - CHM
Emmett Cunningham - IND
John McKew - COO
Aaron Schuchart - OTH
An van Es-Johansson - DRC
Who are the major shareholders of Lumos Pharma Inc?

Here are the top five shareholders of Lumos Pharma Inc based on the size of their shareholding:

Deerfield Management Company, L.P. Hedge Fund
Percentage owned: 11.28% (936k shares)
Stine Seed Farm, Inc. Corporation
Percentage owned: 10.52% (873k shares)
Hawkins (Richard James) Individual Investor
Percentage owned: 8.7% (722k shares)
New Enterprise Associates (NEA) Venture Capital
Percentage owned: 6.35% (527k shares)
Clarus Ventures, LLC Venture Capital
Percentage owned: 5.64% (468k shares)
Similar to LUMO
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.